Evaluating the role of a liver-derived secretory protein, hepatokines, in atherosclerosis

Evaluating the role of a liver-derived secretory protein, hepatokines, in atherosclerosis - The role of hepatokines in atherosclerosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025649

Enrollment

100

Registered

2017-01-20

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have a plant to receive coronary angiography

Exclusion criteria

Exclusion criteria: Criteria for exclusion included cardiac mechanical support, biventricular pacemaker placement, hemodynamically significant uncorrected ventricular arrhythmia, serum creatinine level greater than 2.0 mg/dL, hemofiltration or dialysis, hypersensitivity for iodine, heparin or antiplatelet agent, malignant disease, comorbid conditions with an expected survival of less than 12 months, and active infection disease

Design outcomes

Primary

Measure	Time frame
concentration of hepatokines	—

Secondary

Measure	Time frame
clinical characteristics, such as severity of atherosclerosis, profile of peripheral monocyte, cardiac or carotid artery echo and blood data.	—

Countries

Japan

Contacts

Public ContactSoichiro Usui

Kanazawa University Hospital Cardiovascular Medicine

usuiso@staff.kanazawa-u.ac.jp+81-76-265-2238

Outcome results